Addressing an Unmet Need in EGFR mNSCLC

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-671

By ecancer FEATURING Luis Raez

910 views

February 23, 2024

Disclaimer: On March 1, 2024, The FDA has approved amivantamab-vmjw (RYBREVANT®) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or mNSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.

Comments 1